Graft Versus Host Disease (GvHD) Treatment Market Forecast - Epidemiology & Pipeline Analysis 2022-2027

Description

List of Tables

The report considers the present scenario of the graft versus host disease market and its market dynamics for the period 2022-2027. It covers a detailed overview of several market growth enablers, restraints, and trends. The study covers both the demand and supply sides of the market. It also profiles and analyses leading companies and several other prominent companies operating in the market.

The graft versus host disease market to grow at a CAGR of 7.44% during 2021-2027.

SEGMENT ANALYSIS

Corticosteroids accounted for the significant share of more than 28.97% in the global GvHD treatment market due to its wide recommendation in front line setting.
The acute GVHD (aGVHD) accounted for a significant share of 34.73% in the global graft versus host disease (GVHD) treatment market due to 30% to 50% of hematopoietic stem cell transplant recipients develop acute GVHD.
Males are accounted for the significant share of 59.64% in the global GvHD treatment market due to rise in number of hematopoietic stem cell transplantations.

Market Segmentation by Drug Class

Corticosteroids
Kinase Inhibitors
Calcineurin Inhibitors
TNF-Alpha Inhibitors
Other Class of Drugs

Market Segmentation by Treatment Type

GVHD Prophylaxis
Chronic GVHD
Acute GVHD

Market Segmentation by Gender Type

Males
Females

GEOGRAPHIC ANALYSIS

The United States dominated the graft versus host disease (GVHD) treatment market by geography. However, China is expected to grow faster with a high CAGR in the market. The rise in incidence and prevalence of GVHD patients, presence of key players, and rise in access to health care due to well-established healthcare infrastructure and extensive reach of novel therapeutics are largely driving the United States market.

Market Segmentation by Geography

North America
- US
Europe
- France
- Germany
- Italy
- UK
- Spain
APAC
- China
- Japan

VENDOR ANALYSIS

With more than 134+ molecules in various stages of development, it is expected that new vendors are likely to enter into the market with novel mechanism of action and better safety and efficacy profiles compared to the existing patented commercial drugs for treating GVHD.

Key Players

Incyte
Pharmacyclics
Bristol-Myers Squibb
JCR Pharmaceuticals Co., Ltd.
Takeda Pharmaceutical Co Ltd (Takeda)
MaaT Pharma
XeniKos
Medac GmbH
Mesoblast
Kadmon
Jazz Pharmaceuticals
Gsk
Novartis
Syndax Pharmaceuticals Inc

Other Prominent Vendors

Neovii
ElsaLys Biotech
Mallinckrodt
Regimmune
Roche
Altrubio
CTTQ
Equillium
Janssen (johnson & johnson)
ASC Therapeutics
MSD
Genentech
Sun Pharma
Mink Therapeutics
Pluristem

The Report Covers The following details:

Detailed overview of GVHD, including disease definition, classification, diagnosis, and treatment pattern
Overview of the global graft versus host disease treatment market trends in the eight major markets (8MM)
Historical, current, and projected patient pool of GVHD in the eight major markets (8MM) for the 2018 - 2027 period
Disease, Gender, and Drug Class segmentations of the GVHD in the eight major markets (8MM)
Historical, current, and projected market size & forecast of GVHD in eight major markets (8MM) for the 2018 - 2027 period
In-depth analysis of the market segments, which includes products, treatment, and competitor analysis
Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape
Comprehensive data on emerging trends, market drivers, growth opportunities, and restraints
Detailed overview of marketed drugs with key coverage of developmental activities, including sponsor name, approved indication, territory, collaborations, licensing, mergers and acquisitions, regulatory designations, and other product-related activities
Detailed overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for GVHD across the complete product development cycle, including all clinical and non-clinical stages
Detailed overview of clinical trial activities and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and Geography type for GVHD across all clinical stages
Coverage of dormant and discontinued pipeline projects along with the reasons across GVHD
Coverage of major milestones (product approvals/launches timelines, clinical trial result publications, regulatory designations, licensing & collaborations, research & development progress of pipeline assets) in the GVHD space

Product Code: Sample_Graft Versus Host Disease (GvHD) Treatment Market Forecast - Epidemiology & Pipeline Analysis 2022-2027_Arizton.pdf

CHAPTER - 1 GVHD OVERVIEW

Graft Versus Host Disease - An Overview

CHAPTER - 2 GVHD EPIDEMIOLOGY & OVERVIEW

8MM Historic & Projected Volume of HSCT & Allogeneic - HSCT
8MM Comparative Analysis of HSCT & Allogeneic - HSCT
8MM Historic & Projected Volume of incidence of aGVHD & cGVHD
8MM Comparative Analysis of incidence of aGVHD & cGVHD
US Historic & Projected Volume of HSCT & Allogeneic - HSCT
US Comparative Analysis of HSCT & Allogeneic - HSCT
US Historic & Projected Volume of incidence of aGVHD & cGVHD
US Comparative Analysis of incidence of aGVHD & cGVHD
China Historic & Projected Volume of HSCT & Allogeneic - HSCT
China Comparative Analysis of HSCT & Allogeneic - HSCT
China Historic & Projected Volume of incidence of aGVHD & cGVHD
China Comparative Analysis of incidence of aGVHD & cGVHD
Germany Historic & Projected Volume of HSCT & Allogeneic - HSCT
Germany Comparative Analysis of HSCT & Allogeneic - HSCT
Germany Historic & Projected Volume of incidence of aGVHD & cGVHD
Germany Comparative Analysis of incidence of aGVHD & cGVHD
Japan Historic & Projected Volume of HSCT & Allogeneic - HSCT
Japan Comparative Analysis of HSCT & Allogeneic - HSCT
Japan Historic & Projected Volume of incidence of aGVHD & cGVHD
Japan Comparative Analysis of incidence of aGVHD & cGVHD
France Historic & Projected Volume of HSCT & Allogeneic - HSCT
France Comparative Analysis of HSCT & Allogeneic - HSCT
France Historic & Projected Volume of incidence of aGVHD & cGVHD
France Comparative Analysis of incidence of aGVHD & cGVHD
Italy Historic & Projected Volume of HSCT & Allogeneic - HSCT
Italy Comparative Analysis of HSCT & Allogeneic - HSCT
Italy Historic & Projected Volume of incidence of aGVHD & cGVHD
Italy Comparative Analysis of incidence of aGVHD & cGVHD
UK Historic & Projected Volume of HSCT & Allogeneic - HSCT
UK Comparative Analysis of HSCT & Allogeneic - HSCT
UK Historic & Projected Volume of incidence of aGVHD & cGVHD
UK Comparative Analysis of incidence of aGVHD & cGVHD
Spain Historic & Projected Volume of HSCT & Allogeneic - HSCT
Spain Comparative Analysis of HSCT & Allogeneic - HSCT
Spain Historic & Projected Volume of incidence of aGVHD & cGVHD
Spain Comparative Analysis of incidence of aGVHD & cGVHD

CHAPTER - 3 GVHD MARKET SIZE & OVERVIEW

8MM Historic & Projected Revenue of GVHD
8MM Historic & Projected Revenue of GVHD Snapshot
8MM Major Approved & Off-label Drugs in GVHD
8MM Historic & Projected Revenue Segmentation by Treatment type, Gender type & Drug Class
US Historic & Projected Revenue of GVHD
US Historic & Projected Revenue of GVHD Snapshot
US Historic & Projected Revenue Segmentation by Treatment type, Gender type & Drug Class
China Historic & Projected Revenue of GVHD
China Historic & Projected Revenue of GVHD Snapshot
China Historic & Projected Revenue Segmentation by Treatment type, Gender type & Drug Class
Germany Historic & Projected Revenue of GVHD
Germany Historic & Projected Revenue of GVHD Snapshot
Germany Historic & Projected Revenue Segmentation by Treatment type, Gender type & Drug Class
Japan Historic & Projected Revenue of GVHD
Japan Historic & Projected Revenue of GVHD Snapshot
Japan Historic & Projected Revenue Segmentation by Treatment type, Gender type & Drug Class
France Historic & Projected Revenue of GVHD
France Historic & Projected Revenue of GVHD Snapshot
France Historic & Projected Revenue Segmentation by Treatment type, Gender type & Drug Class
Italy Historic & Projected Revenue of GVHD
Italy Historic & Projected Revenue of GVHD Snapshot
Italy Historic & Projected Revenue Segmentation by Treatment type, Gender type & Drug Class
UK Historic & Projected Revenue of GVHD
UK Historic & Projected Revenue of GVHD Snapshot
UK Historic & Projected Revenue Segmentation by Treatment type, Gender type & Drug Class
Spain Historic & Projected Revenue of GVHD
Spain Historic & Projected Revenue of GVHD Snapshot
Spain Historic & Projected Revenue Segmentation by Treatment type, Gender type & Drug Class

CHAPTER - 4 GVHD MARKETED DRUGS OVERVIEW

GVHD Marketed Drugs - An Overview
GVHD Marketed Drugs - Summary

CHAPTER - 5 GVHD PIPELINE DRUGS OVERVIEW

GVHD Pipeline Drugs - An Overview
GVHD Pipeline Drugs - Snapshot
GVHD Pipeline Drugs Overview & Snapshot - By Disease type
GVHD Pipeline Drugs Overview & Snapshot - By Development Phase
GVHD Pipeline Drugs Overview & Snapshot - By Route of Administration
GVHD Pipeline Drugs Overview & Snapshot - By Mechanism of Action
GVHD Pipeline Drugs Overview & Snapshot - By Molecule type
GVHD Pipeline Drugs Overview & Snapshot - By Geography type

CHAPTER - 6 GVHD CLINICAL TRIALS OVERVIEW

GVHD Clinical Trials Overview Snapshot
GVHD Clinical Trials Overview - By Recruitment Status
GVHD Clinical Trials Overview - By Product type
GVHD Clinical Trials Overview - By Route of Administration
GVHD Clinical Trials Overview - By Molecule type
GVHD Clinical Trials Overview - By Geography type

CHAPTER - 7 GVHD MARKET DYNAMICS

GVHD Treatment Market Drivers
GVHD Treatment Market Constraints
GVHD Treatment Market Trends

CHAPTER - 8 GVHD COMPETITIVE LANDSCAPE

GVHD Competitive Landscape - Marketed Drugs
Unmet Needs & Strategic Recommendations
Competitive Assessment of Off-label & Late-stage Drugs
Key Company Profiles
Competitive Scenario of GVHD Treatment Market
Other Prominent Company Profiles
Key Company Overviews
GVHD Competitive Landscape - Pipeline Drugs
Key Emerging Company Profiles
Key Emerging Company Overviews
Other Prominent Company Profiles

CHAPTER - 9 GVHD MISCELLANEOUS

Key Tentative Drug Approvals Timeline
Key Regulatory Designations
Key Milestones
Deals & Collaborations
Inactive/Discontinued/Dormant Products

CHAPTER - 10 APPENDIX

About Arizton
Research Methodology
List of Abbreviations

Product Code: Sample_Graft Versus Host Disease (GvHD) Treatment Market Forecast - Epidemiology & Pipeline Analysis 2022-2027_Arizton.pdf

LIST OF EXHIBITS

Exhibit 1 HISTORIC & PROJECTED VOLUME OF HSCT IN 8 MAJOR MARKETS
Exhibit 2 HISTORIC & PROJECTED VOLUME OF ALLOGENEIC HSCT IN 8 MAJOR MARKETS
Exhibit 3 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN 8 MAJOR MARKETS (2018-2020)
Exhibit 4 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN 8 MAJOR MARKETS (2021 - 2027)
Exhibit 5 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ACUTE GVHD IN 8 MAJOR MARKETS

Exhibit 6 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CHRONIC GVHD IN 8 MAJOR MARKETS

Exhibit 7 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN 8 MAJOR MARKETS (2018-2020)
Exhibit 8 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN 8 MAJOR MARKETS (2021-2027)
Exhibit 9 HISTORIC & PROJECTED VOLUME OF HSCT IN UNITED STATES
Exhibit 10 HISTORIC & PROJECTED VOLUME OF ALLOGENEIC HSCT IN UNITED STATES
Exhibit 11 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN UNITED STATES (2018-2020)

Exhibit 12 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN UNITED STATES (2021-2027)

Exhibit 13 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ACUTE GVHD IN UNITED STATES
Exhibit 14 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CHRONIC GVHD IN UNITED STATES
Exhibit 15 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN UNITED STATES (2018-2020)
Exhibit 16 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN UNITED STATES (2021-2027)
Exhibit 17 HISTORIC & PROJECTED VOLUME OF HSCT IN CHINA

Exhibit 18 HISTORIC & PROJECTED VOLUME OF ALLOGENEIC HSCT IN CHINA

Exhibit 19 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN CHINA (2018-2020)
Exhibit 20 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN CHINA (2021-2027)
Exhibit 21 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ACUTE GVHD IN CHINA

Exhibit 22 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CHRONIC GVHD IN CHINA

Exhibit 23 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN CHINA (2018-2020)
Exhibit 24 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN CHINA (2021-2027)
Exhibit 25 HISTORIC & PROJECTED VOLUME OF HSCT IN GERMANY

Exhibit 26 HISTORIC & PROJECTED VOLUME OF ALLOGENEIC HSCT IN GERMANY

Exhibit 27 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN GERMANY (2018-2020)
Exhibit 28 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN GERMANY (2021-2027)
Exhibit 29 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ACUTE GVHD IN GERMANY

Exhibit 30 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CHRONIC GVHD IN GERMANY

Exhibit 31 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN GERMANY (2018-2020)
Exhibit 32 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN GERMANY (2021-2027)
Exhibit 33 HISTORIC & PROJECTED VOLUME OF HSCT IN JAPAN
Exhibit 34 HISTORIC & PROJECTED VOLUME OF ALLOGENEIC HSCT IN JAPAN
Exhibit 35 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN JAPAN (2018-2020)
Exhibit 36 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN JAPAN (2021-2027)
Exhibit 37 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ACUTE GVHD IN JAPAN

Exhibit 38 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CHRONIC GVHD IN JAPAN

Exhibit 39 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN JAPAN (2018-2020)
Exhibit 40 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN JAPAN (2021-2027)
Exhibit 41 HISTORIC & PROJECTED VOLUME OF HSCT IN FRANCE
Exhibit 42 HISTORIC & PROJECTED VOLUME OF ALLOGENEIC HSCT IN FRANCE
Exhibit 43 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN FRANCE (2018-2020)

Exhibit 44 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN FRANCE (2021-2027)

Exhibit 45 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ACUTE GVHD IN FRANCE

Exhibit 46 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CHRONIC GVHD IN FRANCE

Exhibit 47 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN FRANCE (2018-2020)
Exhibit 48 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN FRANCE (2021-2027)
Exhibit 49 HISTORIC & PROJECTED VOLUME OF HSCT IN ITALY

Exhibit 50 HISTORIC & PROJECTED VOLUME OF ALLOGENEIC HSCT IN ITALY

Exhibit 51 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN ITALY (2018-2020)
Exhibit 52 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN ITALY (2021-2027)
Exhibit 53 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ACUTE GVHD IN ITALY

Exhibit 54 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CHRONIC GVHD IN ITALY

Exhibit 55 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN ITALY (2018-2020)
Exhibit 56 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN ITALY (2021-2027)
Exhibit 57 HISTORIC & PROJECTED VOLUME OF HSCT IN UNITED KINGDOM

Exhibit 58 HISTORIC & PROJECTED VOLUME OF ALLOGENEIC HSCT IN UNITED KINGDOM

Exhibit 59 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN UNITED KINGDOM (2018-2020)
Exhibit 60 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN UNITED KINGDOM (2021-2027)
Exhibit 61 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ACUTE GVHD IN UNITED KINGDOM

Exhibit 62 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CHRONIC GVHD IN UNITED KINGDOM

Exhibit 63 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN UNITED KINGDOM (2018-2020)
Exhibit 64 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN UNITED KINGDOM (2021-2027)
Exhibit 65 HISTORIC & PROJECTED VOLUME OF HSCT IN SPAIN

Exhibit 66 HISTORIC & PROJECTED VOLUME OF ALLOGENEIC HSCT IN SPAIN

Exhibit 67 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN SPAIN (2018-2020)
Exhibit 68 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN SPAIN (2021-2027)
Exhibit 69 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ACUTE GVHD IN SPAIN

Exhibit 70 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CHRONIC GVHD IN SPAIN

Exhibit 71 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN SPAIN (2018-2020)
Exhibit 72 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN SPAIN (2021-2027)
Exhibit 73 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET IN 8 MAJOR MARKETS
Exhibit 74 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION IN 8 MAJOR MARKETS
Exhibit 75 MAJOR APPROVED & OFF-LABEL DRUGS IN GVHD TREATMENT MARKET
Exhibit 76 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY TREATMENT TYPE IN 8 MAJOR MARKETS
Exhibit 77 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY GENDER IN 8 MAJOR MARKETS
Exhibit 78 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY DRUG CLASS IN 8 MAJOR MARKETS
Exhibit 79 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET IN UNITED STATES
Exhibit 80 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION IN UNITED STATES
Exhibit 81 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY TREATMENT TYPE IN UNITED STATES
Exhibit 82 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY GENDER IN UNITED STATES
Exhibit 83 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY DRUG CLASS IN UNITED STATES
Exhibit 84 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET IN CHINA
Exhibit 85 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION IN CHINA
Exhibit 86 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY TREATMENT TYPE IN CHINA
Exhibit 87 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY GENDER IN CHINA
Exhibit 88 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY DRUG CLASS IN CHINA
Exhibit 89 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET IN GERMANY
Exhibit 90 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION IN GERMANY
Exhibit 91 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY TREATMENT TYPE IN GERMANY
Exhibit 92 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY GENDER IN GERMANY
Exhibit 93 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY DRUG CLASS IN GERMANY
Exhibit 94 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET IN JAPAN
Exhibit 95 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION IN JAPAN
Exhibit 96 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY TREATMENT TYPE IN JAPAN
Exhibit 97 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY GENDER IN JAPAN
Exhibit 98 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY DRUG CLASS IN JAPAN
Exhibit 99 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET IN FRANCE
Exhibit 100 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION IN FRANCE
Exhibit 101 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY TREATMENT TYPE IN FRANCE
Exhibit 102 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY GENDER IN FRANCE
Exhibit 103 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY DRUG CLASS IN FRANCE
Exhibit 104 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET IN ITALY
Exhibit 105 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION IN ITALY
Exhibit 106 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY TREATMENT TYPE IN ITALY
Exhibit 107 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY GENDER IN ITALY
Exhibit 108 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY DRUG CLASS IN ITALY
Exhibit 109 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET IN UNITED KINGDOM
Exhibit 110 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION IN UNITED KINGDOM
Exhibit 111 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY TREATMENT TYPE IN UNITED KINGDOM
Exhibit 112 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY GENDER IN UNITED KINGDOM
Exhibit 113 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY DRUG CLASS IN UNITED KINGDOM
Exhibit 114 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET IN SPAIN
Exhibit 115 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION IN SPAIN
Exhibit 116 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY TREATMENT TYPE IN SPAIN
Exhibit 117 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY GENDER IN SPAIN
Exhibit 118 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY DRUG CLASS IN SPAIN
Exhibit 119 MARKETED DRUGS OVERVIEW IN GVHD TREATMENT MARKET
Exhibit 120 GVHD PIPELINE DRUGS OVERVIEW SNAPSHOT
Exhibit 121 GVHD PIPELINE DRUGS LANDSCAPE SNAPSHOT
Exhibit 122 GVHD PIPELINE DRUGS OVERVIEW BY DISEASE TYPE
Exhibit 123 GVHD PIPELINE DRUGS OVERVIEW BY DEVELOPMENT PHASE
Exhibit 124 GVHD PIPELINE DRUGS OVERVIEW BY ROUTE OF ADMINISTRATION
Exhibit 125 GVHD PIPELINE DRUGS OVERVIEW BY MECHANISM OF ACTION
Exhibit 126 GVHD PIPELINE DRUGS OVERVIEW BY MOLECULE TYPE
Exhibit 127 GVHD PIPELINE DRUGS OVERVIEW BY GEOGRAPHY TYPE
Exhibit 128 KEY TENTATIVE TIMELINE APPROVALS OF PIPELINE DRUHS IN GVHD
Exhibit 129 KEY REGULATORY DESIGNATIONS OF PIPELINE DRUGS IN GVHD
Exhibit 130 INACTIVE/DISCONTINUED PIPELINE DRUGS IN GVHD
Exhibit 131 COMPETITIVE ASSESSMENT OF GVHD PROPHYLAXIS OFF-LABEL & LATE-STAGE PIPELINE DRUGS
Exhibit 132 COMPETITIVE ASSESSMENT OF ACUTE GVHD OFF-LABEL & LATE-STAGE PIPELINE DRUGS
Exhibit 133 COMPETITIVE ASSESSMENT OF CHRONIC GVHD OFF-LABEL & LATE-STAGE PIPELINE DRUGS
Exhibit 134 GVHD CLINICAL TRIALS OVERVIEW SNAPSHOT

LIST OF TABLES

Table 1 KEY MARKET DRIVERS IN GVHD TREATMENT MARKET

Table 2 KEY MARKET CONSTRAINTS IN GVHD TREATMENT MARKET

Table 3 KEY MARKET TRENDS IN GVHD TREATMENT MARKET

Table 4 COMPETITIVE LANDSCAPE OF MARKETED DRUGS IN GVHD TREATMENT MARKET

Table 5 COMPETITIVE SCENARIO OF GVHD TREATMENT MARKET

Table 6 COMPETITIVE LANDSCAPE OF PIPELINE DRUGS IN GVHD TREATMENT MARKET

Graft Versus Host Disease (GvHD) Treatment Market Forecast - Epidemiology & Pipeline Analysis 2022-2027

Description

Table of Contents

List of Tables

TABLE OF CONTENTS

LIST OF EXHIBITS